Menu

Blog

Archive for the ‘biotech/medical’ category: Page 6

Nov 26, 2022

Is pancreatic cancer hereditary? 9 things to know

Posted by in categories: biotech/medical, genetics

Is pancreatic cancer hereditary? Are there any genetic mutations associated with it? Our pancreatic cancer expert Florencia McAllister, M.D., weighs in on these questions and seven more.

Nov 26, 2022

Researchers confirm a primary cause of Alzheimer’s disease

Posted by in categories: biotech/medical, neuroscience

In a study from Yale-NUS College, researchers found evidence that metabolic dysfunction is a primary cause of Alzheimer’s disease is the most common neurodegenerative disease affecting the elderly worldwide, as well as one of the most common causes of dementia. In Singapore, one in 10 people aged 60 or above is believed to suffer from dementia.

Nov 26, 2022

Researchers Say They Are Close To Reversing Aging

Posted by in categories: biotech/medical, life extension

Researchers at Harvard University are investigating whether human genes could reverse the effects of aging. NBC Medical Fellow Dr. Akshay Syal got exclusive access to their lab to discuss the future of how to defy aging.

» Subscribe to NBC News: http://nbcnews.to/SubscribeToNBC
» Watch more NBC video: http://bit.ly/MoreNBCNews.

Continue reading “Researchers Say They Are Close To Reversing Aging” »

Nov 26, 2022

How To Increase Longevity | Prof. Matt Kaeberlein

Posted by in categories: biotech/medical, genetics, information science, life extension

No questions concerning plasma dilution or E5, but a good interview with chapters.


Professor Matt Kaeberlein discusses the Dog Aging Project, longevity, Rapamycin, mTOR, and if we can ‘solve aging’

Continue reading “How To Increase Longevity | Prof. Matt Kaeberlein” »

Nov 26, 2022

Bacteria in tumors may promote cancer

Posted by in category: biotech/medical

Our bodies harbor countless microbes—and so do our tumors, it turns out. Over the past 5 years, researchers have shown cancer tissue contains entire communities of bacteria and fungi. Now, it appears some of the bacteria may be cancer’s accomplices. In a paper in this week, a team led by Susan Bullman of the Fred Hutchinson Cancer Center reports that in oral and colorectal tumors, bacteria live inside cancer cells and boost their production of proteins known to suppress immune responses. The microbial interlopers may set off a chain reaction that prevents the immune system from killing cancerous cells, and they may also help cancer metastasize to other parts of the body.

The study doesn’t entirely clinch the case for a bacterial role in cancer, but it is very suggestive, says Laurence Zitvogel, a tumor immunologist at the Gustave Roussy Institute. “It shows that bacteria in colorectal and oral tumors can actively disturb the immune equilibrium,” she says.

Confirmation that microbes can cause tumors to grow or spread could open up new ways to make cancer treatment more effective, for instance by killing bacteria with antibiotics. And because each type of cancer appears to come with a unique microbiome, researchers are exploring whether microbes could be used as a diagnostic tool to detect cancer early in a blood sample.

Nov 26, 2022

CAR T cell therapy could reach beyond cancer

Posted by in categories: bioengineering, biotech/medical, genetics

Engineered immune cells, known as CAR T cells, have shown the world what personalized immunotherapies can do to fight blood cancers. Now, investigators have reported highly promising early results for CAR T therapy in a small set of patients with the autoimmune disease lupus. Penn Medicine CAR T pioneer Carl June, MD, and Daniel Baker, a doctoral student in Cell and Molecular Biology in the Perelman School of Medicine at the University of Pennsylvania, discuss this development in a commentary published today in Cell.

“We’ve always known that in principle, CAR T therapies could have broad applications, and it’s very encouraging to see early evidence that this promise is now being realized,” said June, who is the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine at Penn Medicine and director of the Center for Cellular Immunotherapies at Penn’s Abramson Cancer Center.

T cells are among the immune system’s most powerful weapons. They can bind to, and kill, other cells they recognize as valid targets, including virus-infected cells. CAR T cells are T cells that have been redirected, through genetic engineering, to efficiently kill specifically defined .

Nov 26, 2022

Scientists Discover a Gene That Could Prevent Alzheimer’s Disease

Posted by in categories: biotech/medical, neuroscience

Researchers at the University of Colorado Anschutz find that the overexpression of a gene improves learning and memory in Alzheimer’s.

Alzheimer’s disease is a disease that attacks the brain, causing a decline in mental ability that worsens over time. It is the most common form of dementia and accounts for 60 to 80 percent of dementia cases. There is no current cure for Alzheimer’s disease, but there are medications that can help ease the symptoms.

Nov 26, 2022

Understanding Senescence

Posted by in categories: biotech/medical, life extension

Dr. Campisi has been at the forefront of studying cellular senescence for decades, revealing the mysteries of these not-exactly-dead cells and their role in many diseases of aging. In this episode, she joins her colleague Gordon to discuss the characteristics and function of senescent cells, as well as promising interventions on the horizon. Judy also describes how to get lucky in science by being prepared to see the unexpected.

Nov 26, 2022

CRISPR vs breast, colon, lung cancer: First human trial goes well

Posted by in categories: bioengineering, biotech/medical

A small human trial has tested CRISPR gene editing technology in the treatment of solid cancer tumors, including breast, colon, and lung cancer, with promising results.

Nov 26, 2022

Occuity lands £343k grant to develop optical diabetes screening device

Posted by in categories: biotech/medical, finance, life extension

DISCLOSURE: Longevity. Technology (a brand of First Longevity Limited) has been contracted by the company featured in this article to support its current funding round. Qualifying investors can find out more via the Longevity. Technology investment portal.

MedTech start-up Occuity has received a £343,000 Innovate UK Biomedical Catalyst (BMC) Award to fund the next stage of the development of its innovative AGE reader: an optical medical device that will enable non-invasive screening of diabetes in non-clinical settings such as opticians and pharmacies.

Biomedical Catalyst is the flagship Innovate UK grant funding competition for supporting UK health & life sciences SMEs. It supports the development of innovative solutions to health and healthcare challenges by providing financial support to accelerate the route to commercialisation.

Continue reading “Occuity lands £343k grant to develop optical diabetes screening device” »

Page 6 of 1,928First345678910Last